(CercleFinance.com) – GSK today announced positive results from a phase IIa study demonstrating that GSK3036656, a first-in-class investigational anti-tuberculosis agent, was ‘well tolerated’ and exhibited ‘early bactericidal activity when administered orally in low doses, after 14 days of treatment’.
These data may serve as a basis for phase IIb/c studies, with the aim of contributing to shorter, simpler and better tolerated treatment regimens for patients with tuberculosis.
According to GSK, these results demonstrate the potential of GSK3036656 to be a component of simpler treatment regimens in the future, which could help fight the tuberculosis epidemic.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
